17. 1984 ATV Owners Manuals. (Will be available for viewing in Room 100).
18. 169 in depth investigation reports (IDIs), referenced in text.
19. All other ATV related IDIs.
29. April 20, 1985, Meeting Log of SVIA/CPSC meeting.
36. February 21, 1985, T. Karrels, ECCS, to N. Marchica, OPM, Subject: Snowmobiles and Off Highway Motorcycles in Use.
Documents in the Record.
38. February 20, 1985, Briefing Package to Commission, Subject: Update of Actions on ATVs.
41. Restricted April 4, 1985, Commission Minutes of Decision: ATVs; Compliance and OGC Options.
42. March 19, 1985, N. Marchica, OPM, to Commission, Subject: ATVs.
43. May 1, 1984, A. Esch, HS, to N. Marchica, OPM, Subject: ATVs.
44. March 25, 1985, Meeting Log, ES and NHTSA.
48. March 20, 1984, H. Tzuker, EPHA, to N. Marchica, OPM, Subject: Futher Information on ATVs.
49. Copyrighted materials; Newsletter cannot be reproduced.
52. March 30, 1985, letter from E. Gunn, Honda, to E. Haught, CACA, Subject: Update of Recent Activities.
53. Meeting Log of March 26, 1985, Meeting Between CPSC Staff and Representatives of American Honda, Subject: Design and Development of the Honda ATC.
54. March 20, 1985, Memorandum to ATV Safety Task Force and Interested Parties, from S. Halbert, 4-H Youth Development, Subject: Future Program/ Media Efforts.
55. Assembly Bill 106, State of Wisconsin, Subject: Regulations on Restrictions of ATVs.
56. 1984, Teong Eng Tang "Analysis of Three Wheeled All-Terrain Vehicles/Rider System Dynamics", Abstract of Dissertation Submitted to Graduate Faculty, Iowa State University.
57. February 7, 1985, K. Giles, OPA, to N. Marchica, OPM, Subject: Information and Training on ATVs.
58. March 27, 1985, V. Brown, ES/SH, to the Commission, Subject: State Laws Containing Minimum Operator Age Requirements for All Terrain Vehicles.
62. Copyrighted materials may not be reproduced.
63. March 29, 1985, D. Kaplan, ES, to Commission, Subject: Documents on ATVs (Engineering and Other Studies, Articles).
64. Federal Register Notice regarding Jackson, Mississippi Public Hearings.

[FR Doc. 85-13107 Filed 5-30-85; 8:45 am]
BILLING CODE 6355-01-M

DEPARTMENT OF JUSTICE
Drug Enforcement Administration

21 CFR Part 1308

Schedules of Controlled Substances; Proposed Removal of Nalbuphine From Control

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of proposed rulemaking.

SUMMARY: This notice proposes the removal of the substance, nalbuphine, and salts thereof, from control under the Controlled Substances Act (21 U.S.C. 801 et seq.). Nalbuphine is currently a Schedule II narcotic by virtue of its derivation from the Schedule II opiod thebaine. This action results from the Acting Administrator's findings, based largely upon the recommendation of the Acting Assistant Secretary for Health, that nalbuphine does not have sufficient potential for abuse or abuse liability to justify its continued control in any schedule.

DATE: Comments and objections must be received on or before July 30, 1985.

ADDRESS: Comments and objections may be submitted in quintuplicate to the Acting Administrator, Drug Enforcement Administration, 1200 New York Street, NW, Washington, D.C. 20537. Attention: DEA Federal Register Representative.

FOR FURTHER INFORMATION CONTACT: Howard McClain, Jr., Chief, Drug Control Section, Drug Enforcement Administration

HeinOnline -- 50 Fed. Reg. 23144 1985
Administration, Washington, D.C. 20537.

Telephone (202) 633-1366.

SUPPLEMENTARY INFORMATION:

List of Subjects in 21 CFR Part 1308

Administrative practice and procedure, Drug traffic control, Narcotics, Prescription drugs.

Nalmefene is a controlled substance in Schedule II of the Controlled Substances Act (CSA) (21 U.S.C. 812(c) Schedule II (a)(1); § 1308.12(b)(3)), Title 21 of the Code of Federal Regulations (CFR). Chemically, nalmefene is 17-(cyclopentylmethyl)-4,5-epoxy-6-methylene-2-norbornan-3,14-diol; nalmefene is a derivative of the narcotic antagonist naltrexone and the Schedule II opioid thebaine.

On December 12, 1984, Key Pharmaceuticals, Inc., Miami, Florida, pursuant to 21 U.S.C. 811, et seq., petitioned the Drug Enforcement Administration to initiate proceedings for removing nalmefene entirely from the schedules of the CSA. In addition, Key Pharmaceuticals, Inc. submitted data in support of its request to decontrol nalmefene. The Drug Enforcement Administration reviewed this data and forwarded the decontrol petition and its own comments in that regard in a letter dated January 17, 1985 to the Department of Health and Human Services for a scientific and medical evaluation and recommendation as to the merits of the petition, in accordance with 21 U.S.C. 811(b). In a letter dated March 14, 1985, the Acting Assistant Secretary for Health, on behalf of the Secretary, provided the Acting Administrator with his evaluation, based upon the recommendation of the Food and Drug Administration which included the endorsement of their Drug Abuse Advisory Committee that convened on January 17, 1985, "that nalmefene be removed from the schedules of the CSA and placed in an excluded narcotic status."

Based upon the review of the Drug Enforcement Administration and upon the scientific and medical evaluation and recommendation of the Secretary of the Department of Health and Human Services, received pursuant to 21 U.S.C. 811(b), the Acting Administrator finds that nalmefene possesses sufficient potential for abuse to justify its continued control in any schedule of the CSA.

PART 1308—[AMENDED]

Therefore, under the authority vested in the Attorney General by section 201(a) of the CSA (21 U.S.C. 811(a)), and delegated to the Acting Administrator of the Drug Enforcement Administration by regulations of the Department of Justice (28 CFR Part 0.300), the Acting Administrator hereby proposes that 21 CFR 1308.12 be amended as follows:

1. The authority citation for 21 CFR Part 1308 continues to read as follows:


2. Section 1308.12(b)(1) would be revised to read as follows:

§ 1308.12 Schedule II

(b) ... (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrophan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including the following:

(1) Raw opium ........................................ 9600
(2) Opium extracts .................................... 9610
(3) Opium fluid ....................................... 9620
(4) Powdered opium ................................... 9639
(5) Granulated opium .................................. 9640
(6) Tincture of opium .................................. 9630
(7) Codine .............................................. 9050
(8) Ethylmorphine ..................................... 9190
(9) Etorphine hydrochloride ......................... 9059
(10) Hydrocodone ..................................... 9139
(11) Hydromorphone .................................. 9130
(12) Metadone ......................................... 9250
(13) Morphine ......................................... 9300
(14) Oxycodone ........................................ 9143
(15) Oxymorphone ..................................... 9652
(16) Thebaine ......................................... 9333

Interested persons are invited to submit their comments, objections or requests for a hearing in writing with regard to this proposal. Requests for a hearing shall state with particularity the issues concerning which the person desires to be heard. All correspondence regarding this matter should be submitted in quintuplicate to the Acting Administrator, Drug Enforcement Administration, 1405 Eye Street, NW., Washington, D.C. 20537, Attention: DEA Federal Register Representative.

In the event that comments, objections or requests for a hearing raise one or more issues which the Acting Administrator finds warrant a hearing, the Acting Administrator shall order a public hearing by notice in the Federal Register summarizing the issues to be heard and setting the time for the hearings which will not be less than 30 days after the date of the notice.

If no objections presenting grounds for a hearing on this proposal are received within the time limitation or if interested parties waive or are deemed to have waived their opportunity for a hearing or to participate in a hearing, the Acting Administrator, after giving consideration to written comments and objections, will issue his final order pursuant to 21 CFR 1308.48 without a hearing.

Pursuant to 5 U.S.C. 605(b), the Acting Administrator certifies that removal of nalmefene from control under the Controlled Substances Act is a deregulation action which will have no adverse impact upon small businesses or other entities whose interests must be considered under the Regulatory Flexibility Act (Pub. L. 96–354). In addition, nalmefene has not been approved by the Food and Drug Administration for use in medical treatment or to have accepted safety for use as a drug or other substance under medical supervision in the United States.

In accordance with the provisions of 21 U.S.C. 811(a), this proposal to remove nalmefene from Schedule II is a formal rulemaking “on the record after opportunity for a hearing.” Such proceedings are conducted pursuant to the provisions of 5 U.S.C. 556 and 557 and as such have been exempted from the consultation requirements of Executive Order 12291.


John C. Lanyak,
Acting Administrator, Drug Enforcement Administration.

[FR Doc. 85–1309 Filed 5–30–85; 8:45 am]

BILLING CODE 4410–09–M

VETERANS ADMINISTRATION

38 CFR Part 21

Veterans Education: Delegation of Authority

AGENCY: Veterans Administration.

ACTION: Proposed rules.

SUMMARY: A discrepancy exists between two VA regulations as to who has authority to approve special restorative training of more than 12 months for children entitled to dependents’ educational assistance. One of those regulations is amended to bring it into agreement with the other. The Director, Vocational Rehabilitation and Counseling Service is delegated the authority to make these decisions.

DATES: Comments must be received on or before July 1, 1985.

ADDRESSES: Send written comments to: Administrator of Veterans’ Affairs (271A), Veterans Administration, 810 Vermont Avenue, NW, Washington, DC 20420. All written comments received will be available for public inspection.